Livforsakringsbolaget Skandia Omsesidigt Has $7.58 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,632 shares of the biopharmaceutical company’s stock after purchasing an additional 118 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Regeneron Pharmaceuticals were worth $7,577,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Norges Bank bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $697,296,000. FMR LLC boosted its stake in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares in the last quarter. International Assets Investment Management LLC lifted its position in Regeneron Pharmaceuticals by 76,169.5% during the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after buying an additional 590,314 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its position in Regeneron Pharmaceuticals by 57,848.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after buying an additional 581,379 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Regeneron Pharmaceuticals by 129.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after buying an additional 122,103 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the sale, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of REGN traded up $7.05 on Wednesday, hitting $901.19. The company’s stock had a trading volume of 468,666 shares, compared to its average volume of 495,554. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm’s fifty day moving average price is $955.94 and its 200-day moving average price is $890.45. The firm has a market capitalization of $98.91 billion, a price-to-earnings ratio of 25.73, a P/E/G ratio of 2.62 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the firm posted $10.96 EPS. The business’s revenue was up .6% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on REGN shares. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Finally, Bank of America boosted their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $970.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.